Covid-19: Arthritis drugs improve survival in intensive care patients, shows study

Two rheumatoid arthritis drugs will now be used to treat the patients with severe covid-19 in intensive care, after new findings have shown that they significantly improve survival and cut time spent hospital by a week 10 days. Results from REMAP-CAP trial showed interleukin 6 receptor antagonists tocilizumab sarilumab reduced mortality 35.8% 27.3% compared standard care—an absolute reduction of 8.5% relative 24%.1 The benefit was seen when were given within 24 hours entering care addition corticosteroid, such as dexamethasone. Anthony Gordon, professor anaesthesia critical at Imperial College London chief investigator study, told Science Media Centre briefing: “If we 12 it would save one life. This is very big effect really exciting.” The Department Health Social Care said supplies are already available hospitals updated guidance issued trusts across UK encouraging …